NxStage Medical, Inc. (NASDAQ:NXTM)‘s stock had its “hold” rating reiterated by equities research analysts at Northland Securities in a report issued on Monday. They currently have a $30.00 price objective on the medical device company’s stock. Northland Securities’ price target points to a potential upside of 1.11% from the company’s previous close.

The analysts wrote, “We continue to move our PD program forward at an impressive pace…We continue to firmly believe that by keeping our regulatory timelines and pathway confidential, we’re protecting a significant value opportunity. Let me be clear, we both have the opportunity to do great things for patients, bringing new technology to the market that makes PD easier and better.””

A number of other equities research analysts have also issued reports on the stock. Jefferies Group LLC cut their price target on shares of NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th. Craig Hallum lowered shares of NxStage Medical from a “buy” rating to a “hold” rating in a report on Monday. BidaskClub lowered shares of NxStage Medical from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Canaccord Genuity restated a “buy” rating and set a $32.00 price target on shares of NxStage Medical in a report on Monday, May 8th. Finally, BTIG Research restated a “buy” rating and set a $27.00 price target on shares of NxStage Medical in a report on Wednesday, May 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $29.67.

Shares of NxStage Medical (NXTM) traded up 28.22% on Monday, hitting $29.67. 25,257,155 shares of the stock were exchanged. The company’s market cap is $1.95 billion. The firm’s 50-day moving average is $24.08 and its 200-day moving average is $25.81. NxStage Medical has a one year low of $20.45 and a one year high of $30.80.

NxStage Medical (NASDAQ:NXTM) last released its earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). NxStage Medical had a negative net margin of 1.25% and a negative return on equity of 2.31%. The business had revenue of $92.20 million for the quarter, compared to the consensus estimate of $96.47 million. During the same period in the previous year, the firm earned ($0.03) EPS. The business’s revenue for the quarter was up .0% on a year-over-year basis. On average, equities analysts forecast that NxStage Medical will post ($0.03) EPS for the current fiscal year.

WARNING: “NxStage Medical, Inc. (NASDAQ:NXTM) Receives Hold Rating from Northland Securities” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/07/nxstage-medical-inc-nasdaqnxtm-receives-hold-rating-from-northland-securities.html.

In other NxStage Medical news, President Joseph E. Turk, Jr. sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $25.19, for a total value of $25,190.00. Following the completion of the sale, the president now directly owns 75,903 shares of the company’s stock, valued at $1,911,996.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Matthew W. Towse sold 4,300 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $21.36, for a total transaction of $91,848.00. Following the completion of the sale, the senior vice president now directly owns 29,637 shares of the company’s stock, valued at $633,046.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,150 shares of company stock worth $669,351. Company insiders own 4.70% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in NxStage Medical during the first quarter valued at approximately $140,000. Ameritas Investment Partners Inc. acquired a new stake in NxStage Medical during the first quarter valued at approximately $148,000. Menta Capital LLC acquired a new stake in NxStage Medical during the first quarter valued at approximately $212,000. Jane Street Group LLC acquired a new stake in NxStage Medical during the first quarter valued at approximately $213,000. Finally, PEAK6 Investments L.P. acquired a new stake in NxStage Medical during the first quarter valued at approximately $214,000. 91.11% of the stock is owned by institutional investors.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Analyst Recommendations for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.